Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial

Journal:
The Lancet
Published:
Affiliations:
26
Authors:
158
Institutions Authors Share
Medical University of Vienna (MUW), Austria
1.580000
0.06
START Carolinas, United States of America (USA)
1.040000
0.04
NIHR Barts Biomedical Research Centre (BRC), United Kingdom (UK)
1.040000
0.04
Krasnoyarsk State Medical Academy, Russia
1.040000
0.04
San Carlos Clinical Hospital (HCSC), Spain
1.040000
0.04
St. Antonius Hospital, Netherlands
1.040000
0.04
AstraZeneca, United Kingdom (UK)
1.040000
0.04
AstraZeneca Gaithersburg, MD, United States of America (USA)
1.040000
0.04
Hospital Universitario 12 de Octubre, Spain
1.040000
0.04
Centre Hospitalier Universitaire d'Angers (CHU d'Angers), France
1.040000
0.04
University Hospitals Leuven (UZ Leuven), Belgium
1.040000
0.04
AstraZeneca Cambridge, United Kingdom (UK)
1.040000
0.04
Centre Hospitalier de l’Université Laval (CHUL) Research Centre, UL, Canada
1.040000
0.04
Medical University of Warsaw (MUW), Poland
1.040000
0.04
Urologicum Duisburg, Germany
1.040000
0.04
North-Western State Medical University named after I.I. Mechnikov (NWSMU), Russia
1.040000
0.04
Clinical Research Center sp. z o.o., Poland
1.040000
0.04
Icon Group, Australia
1.040000
0.04
University of Tsukuba, Japan
1.040000
0.04
Saint-Petersburg Clinical Hospital of the Russian Academy of Sciences, Russia
1.040000
0.04
Osaka Metropolitan University (OMU), Japan
1.040000
0.04
Yokohama City University Medical Center, YCU, Japan
1.040000
0.04
Autonomous University of Barcelona (UAB), Spain
1.040000
0.04
Charité - University Medicine Berlin, Germany
0.540000
0.02